Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: THY022
MIFTS: 57

Thymic Carcinoma

Categories: Cancer diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Thymic Carcinoma

About this section

MalaCards integrated aliases for Thymic Carcinoma:

Name: Thymic Carcinoma 12 74 58 54 15 17
Malignant Thymoma 12 58
Thymoma, Malignant 12

Characteristics:

Orphanet epidemiological data:

58
thymic carcinoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: any age;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Immune diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:3284
MeSH 43 D013945
NCIt 49 C7569
SNOMED-CT 67 444374006
ICD10 via Orphanet 33 C37
UMLS via Orphanet 72 C0205969 C1322286
Orphanet 58 ORPHA99868
UMLS 71 C0205969
Sources

Summaries for Thymic Carcinoma

About this section
Disease Ontology : 12 A thymus cancer that derives from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found.

MalaCards based summary : Thymic Carcinoma, also known as malignant thymoma, is related to lymphoepithelioma-like thymic carcinoma and type c thymoma. An important gene associated with Thymic Carcinoma is KIT (KIT Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Cytoskeletal Signaling and Hematopoietic Stem Cells and Lineage-specific Markers. The drugs Fentanyl and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include thymus, lung and thyroid, and related phenotypes are mediastinal lymphadenopathy and neoplasm of the thymus

Wikipedia : 74 Thymic carcinoma is a rare type of thymus gland cancer. It usually spreads, has a high risk of... more...

Sources

Related Diseases for Thymic Carcinoma

About this section

Diseases related to Thymic Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 843)
# Related Disease Score Top Affiliating Genes
1 lymphoepithelioma-like thymic carcinoma 34.5 KIT CD5
2 type c thymoma 33.4 KIT CD5
3 thymus adenocarcinoma 33.0 KRT20 CEACAM5 CD5
4 epithelial malignant thymoma 32.3 TG CD5
5 thymus cancer 31.5 TP53 PTPRC NKX2-1 KRT7 KIT EGFR
6 thymic epithelial tumor 31.3 KIT CD5
7 exanthem 30.8 KIT EGFR CD274
8 secretory meningioma 30.5 MUC1 KRT7 CEACAM5
9 pneumothorax 30.4 NKX2-1 MUC1 CALB2
10 thymus sarcomatoid carcinoma 30.3 SYP CD5
11 spindle cell thymoma 30.2 MUC1 ENO2 CD5 CALB2
12 appendix adenocarcinoma 30.1 SYP KRT7 KRT20 CEACAM5
13 thymus basaloid carcinoma 30.1 PAX8 NKX2-1 CD5
14 myoma 30.0 TP53 KIT EGFR
15 thymus lipoma 29.9 KRT20 KRT19
16 benign mesothelioma 29.8 PAX8 KRT7 CEACAM5 CALB2
17 cystitis 29.8 TP53 KRT7 KRT20 KIT
18 malignant fibrous histiocytoma 29.8 TP53 PTPRC MUC1 KIT
19 choroid plexus cancer 29.8 TP53 SYP CEACAM5
20 carcinoid tumors, intestinal 29.7 SYP NKX2-1 ENO2
21 pancytopenia 29.7 TP53 PTPRC KIT CD5
22 lung oat cell carcinoma 29.7 SYP ENO2
23 fibrous histiocytoma 29.6 TP53 KIT ENO2
24 pleural disease 29.5 TP53 EGFR CEACAM5 CALB2
25 ectopic thymus 29.5 TG NKX2-1 CD5
26 lymphoma 29.4 TP53 PTPRC MUC1 KIT EGFR CD5
27 gastrointestinal stromal tumor 29.4 TP53 SYP KIT ENO2 EGFR
28 keratinizing squamous cell carcinoma 29.4 TP53 NKX2-1 KRT7 EGFR CEACAM5
29 exophthalmos 29.4 TG SYP ENO2
30 lymphoepithelioma-like carcinoma 29.3 MUC1 KRT7 KRT20 KRT19 KRT18 ENO2
31 leukemia, chronic lymphocytic 29.3 TP53 PTPRC KIT EGFR CD5 CD274
32 sarcoma, synovial 29.3 MUC1 KRT7 KRT19 KIT CALB2
33 meningioma, familial 29.2 TP53 SYP ENO2 EGFR
34 leukemia, acute myeloid 29.2 TP53 PTPRC KIT EGFR CD5 CD274
35 adenocarcinoma 29.1 TP53 NKX2-1 MUC1 KRT7 KRT20 KIT
36 malignant pleural mesothelioma 29.1 TP53 NKX2-1 MUC1 EGFR CD274 CALB2
37 neuroendocrine tumor 29.1 SYP NKX2-1 KRT20 KRT19 ENO2 CD274
38 myeloma, multiple 29.1 TP53 PTPRC MUC1 KIT EGFR CD5
39 lung squamous cell carcinoma 28.9 TP63 TP53 KRT19 EGFR CEACAM5 CD274
40 neuroblastoma 28.9 TP53 SYP KIT ENO2 EGFR CD274
41 papillary adenocarcinoma 28.9 TP53 NKX2-1 MUC1 KRT7 KRT19 CEACAM5
42 spindle cell carcinoma 28.9 TP63 SYP MUC1 KRT7 KRT19 KRT18
43 papillary thymic adenocarcinoma 28.9 TG SYP CEACAM5 CD5 CALB2
44 squamous cell carcinoma 28.8 TP63 TP53 MUC1 KRT7 KRT19 EGFR
45 mesothelioma, malignant 28.8 NKX2-1 MUC1 KRT7 KRT20 KRT19 CEACAM5
46 mediastinal cancer 28.8 SYP PTPRC NKX2-1 KRT7 KIT ENO2
47 adenoid cystic carcinoma 28.5 TP63 TP53 MUC1 KRT7 KRT20 KRT19
48 adenoma 28.5 TP53 TG SYP MUC1 KRT7 KRT20
49 goiter 28.5 TG PAX8 NKX2-1 KRT19
50 oncocytoma 28.3 SYP NKX2-1 MUC1 KRT7 KRT20 KRT19

Graphical network of the top 20 diseases related to Thymic Carcinoma:



Diseases related to Thymic Carcinoma
Sources

Symptoms & Phenotypes for Thymic Carcinoma

About this section

Human phenotypes related to Thymic Carcinoma:

58 31 (show all 13)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 mediastinal lymphadenopathy 58 31 hallmark (90%) Very frequent (99-80%) HP:0100721
2 neoplasm of the thymus 58 31 hallmark (90%) Very frequent (99-80%) HP:0100521
3 dyspnea 58 31 frequent (33%) Frequent (79-30%) HP:0002094
4 cough 58 31 frequent (33%) Frequent (79-30%) HP:0012735
5 chest pain 58 31 frequent (33%) Frequent (79-30%) HP:0100749
6 palpebral edema 58 31 frequent (33%) Frequent (79-30%) HP:0100540
7 diaphragmatic paralysis 58 31 frequent (33%) Frequent (79-30%) HP:0006597
8 abnormal vena cava morphology 58 31 frequent (33%) Frequent (79-30%) HP:0005345
9 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
10 hyperhidrosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000975
11 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
12 fatigable weakness 58 31 occasional (7.5%) Occasional (29-5%) HP:0003473
13 edema 58 Frequent (79-30%)

MGI Mouse Phenotypes related to Thymic Carcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.23 CD274 EGFR ENO2 KIT KRT19 KRT7
2 nervous system MP:0003631 10.13 CALB2 CD5 EGFR ENO2 KIT KRT19
3 digestive/alimentary MP:0005381 10.01 EGFR KIT KRT19 NKX2-1 PTPRC TG
4 craniofacial MP:0005382 9.98 EGFR ENO2 KIT KRT19 PAX8 TP53
5 no phenotypic analysis MP:0003012 9.96 CD274 CD5 EGFR KIT KRT19 NKX2-1
6 neoplasm MP:0002006 9.91 EGFR KIT KRT19 NKX2-1 PTPRC TP53
7 normal MP:0002873 9.9 CALB2 CD5 EGFR KIT KRT19 NKX2-1
8 respiratory system MP:0005388 9.56 EGFR ENO2 KIT KRT19 NKX2-1 PTPRC
9 skeleton MP:0005390 9.36 CD274 EGFR KIT KRT19 NKX2-1 PAX8
Sources

Drugs & Therapeutics for Thymic Carcinoma

About this section

Drugs for Thymic Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
2
Etoposide Approved Phase 3 33419-42-0 36462
3 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
4 Analgesics Phase 3
5 Cola Phase 3
6 Liver Extracts Phase 3
7 Anesthetics Phase 3
8 Narcotics Phase 3
9 Analgesics, Opioid Phase 3
10 Anesthetics, General Phase 3
11 Anesthetics, Intravenous Phase 3
12 Etoposide phosphate Phase 3
13
Everolimus Approved Phase 2 159351-69-6 70789204 6442177
14
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
15
leucovorin Approved Phase 2 58-05-9 6006 143
16
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
17
Octreotide Approved, Investigational Phase 2 83150-76-9 383414 6400441
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3
19
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
20
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
21
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
22
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
23
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
24
Melphalan Approved Phase 2 148-82-3 460612 4053
25
Busulfan Approved, Investigational Phase 2 55-98-1 2478
26 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
27
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
28
Nedaplatin Approved, Investigational Phase 2 95734-82-0
29
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
30
nivolumab Approved Phase 2 946414-94-4
31
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
32
ramucirumab Approved, Investigational Phase 2 947687-13-0
33
Durvalumab Approved, Investigational Phase 2 1428935-60-7
34
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
35
Pembrolizumab Approved Phase 2 1374853-91-4
36
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
37
Coal tar Approved Phase 1, Phase 2 8007-45-2
38
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
39
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 441203 84093
40
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
41
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
42
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
43
Belinostat Approved, Investigational Phase 1, Phase 2 866323-14-0
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
45
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
46 Amrubicin Investigational Phase 2 110267-81-7
47
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
48
Lexatumumab Investigational Phase 2 845816-02-6
49
Tremelimumab Investigational Phase 2 745013-59-6
50
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma Recruiting NCT02633514 Phase 3 Cisplatin;Etoposide
3 Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Unknown status NCT02049047 Phase 2 Everolimus
4 An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND Unknown status NCT02307500 Phase 2 Regorafenib
5 Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00198133 Phase 2 Premetrexed (Alimta)
6 A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma Completed NCT02623127 Phase 2 Sunitinib
7 A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors Completed NCT01312324 Phase 2 neoadjuvant docetaxel/cisplatin
8 Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy Completed NCT00965250 Phase 2 IMC-12
9 Phase II Study Of Carboplatin Plus Paclitaxel Treatment Of Advanced Thymoma Or Thymic Carcinoma Completed NCT00010257 Phase 2 carboplatin;paclitaxel
10 Phase II Study of Octreotide Treatment of Advanced, Recurrent Thymoma Completed NCT00003283 Phase 2 octreotide acetate;prednisone
11 Phase II Study of Trimodality Therapy for Patients With Thymoma or Thymic Carcinoma at Significant Risk for Recurrence Completed NCT00387868 Phase 2 cisplatin and etoposide
12 A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma Completed NCT00369889 Phase 2 bevacizumab;Erlotinib
13 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
14 A Multicenter Phase II Study of Belinostat (PXD-101) in Previously Chemotherapy Treated Thymoma and Thymic Carcinoma Completed NCT00589290 Phase 2 Belinostat (PDX101)
15 A Phase II Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Completed NCT01364727 Phase 2 Amrubicin
16 Radiofrequency Ablation of Pulmonary Malignancy Completed NCT00024076 Phase 2
17 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children With Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases Completed NCT00003662 Phase 2 busulfan;cyclophosphamide;cyclosporine;melphalan;methylprednisolone
18 A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Patients With Severe Aplastic Anemia, Inborn Errors in Metabolism, or Inherited Hematologic Stem Cell Disorders Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
19 An Open-Label, Dose-escalation, Phase I/IIa Study to Determine the Maximum Tolerated Dose, Recommended Dose, Efficacy, Pharmacokinetics and Pharmacodynamics of the Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, E-3810, Given Orally as Single Agent to Patients With Advanced Solid Tumours Completed NCT01283945 Phase 1, Phase 2 Lucitanib
20 A Prospective, Phase â…¡ Study of Thymosin a1 During Chemoradiotherapy For Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03663764 Phase 2 Thymosin a1
21 Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy Recruiting NCT03134118 Phase 2 Nivolumab
22 Phase 1/2 Study to Evaluate the Safety and Preliminary Activity of Nivolumab in Combination With Vorolanib in Patients With Refractory Thoracic Tumors Recruiting NCT03583086 Phase 1, Phase 2 VEGFR/PDGFR Dual Kinase Inhibitor X-82
23 A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting NCT01325441 Phase 1, Phase 2 BBI608;Paclitaxel
24 Improving Treatment Strategies in Thymic Epithelial Tumors: a TYME Collaborative Effort Recruiting NCT03921671 Phase 2
25 A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma Recruiting NCT03463460 Phase 2 Sunitinib Malate
26 Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) Recruiting NCT03449173 Phase 2 Sunitinib
27 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
28 A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma Recruiting NCT03694002 Phase 2 Carboplatin;Paclitaxel
29 A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Recruiting NCT03466827 Phase 2 Selinexor
30 A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT) Recruiting NCT03193437 Phase 2 Open Label Selinexor
31 A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors Recruiting NCT02938793 Phase 2 Durvalumab;Tremelimumab
32 Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas Active, not recruiting NCT02364076 Phase 2 Pembrolizumab;Epacadostat
33 A Phase II Trial of Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (BMS #CA225-331/Lilly Trial Alias I4E-US-X007) Active, not recruiting NCT01025089 Phase 2 Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
34 A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy Active, not recruiting NCT01621568 Phase 2 Sunitinib
35 A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Active, not recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
36 An Open-Label, Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma Not yet recruiting NCT04321330 Phase 2 Atezolizumab
37 A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Not yet recruiting NCT04417660 Phase 2 M7824
38 Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Previously Treated With Chemotherapy Terminated NCT01011439 Phase 2 Milciclib Maleate
39 Phase II Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy Terminated NCT01301391 Phase 2 Milciclib Maleate
40 A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma Terminated NCT00818090 Phase 2 paclitaxel and cisplatin
41 Phase II Trial of AZD0530 for Patients With Relapsed/Refractory Thymic Malignancies (Thymoma and Thymic Carcinoma) Terminated NCT00718809 Phase 2 saracatinib
42 A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic Malignancies Terminated NCT01100944 Phase 1, Phase 2 PXD101with cisplatin+doxorubicin+cyclophosphamide
43 Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma Completed NCT00314873 Phase 1 Gleevec (imatinib)
44 Phase I Dose Escalation Study of Accelerated Fractionation With Esophageal Sparing Using Intensity-Modulated Radiation Therapy for Locally-Advanced Thoracic Malignancies Including a Prospective Assessment of Esophageal Motion and Radiation-Induced Esophageal Injury Completed NCT00921739 Phase 1
45 A Phase I Clinical Trial of Intrapleural Adenoviral-Mediated Interferon-beta (IFN-ß) Gene Transfer for Pleural Malignancies Completed NCT00066404 Phase 1
46 A Phase I Study of an Oral Histone Deacetylase Inhibitor, MS-275, in Refractory Solid Tumors and Lymphomas Completed NCT00020579 Phase 1 entinostat
47 An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma Recruiting NCT03556228 Phase 1 VMD-928 300-mg Capsules
48 Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies Recruiting NCT03102320 Phase 1 Cisplatin;Gemcitabine;Anetumab ravtansine (BAY94-9343)
49 Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma Recruiting NCT03295227 Phase 1 Pembrolizumab
50 Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas Terminated NCT01143545 Phase 1 Celecoxib;cyclophosphamide

Search NIH Clinical Center for Thymic Carcinoma

Sources

Genetic Tests for Thymic Carcinoma

About this section
Sources

Anatomical Context for Thymic Carcinoma

About this section

MalaCards organs/tissues related to Thymic Carcinoma:

40
Thymus, Lung, Thyroid, Bone, Lymph Node, T Cells, Brain
Sources

Publications for Thymic Carcinoma

About this section

Articles related to Thymic Carcinoma:

(show top 50) (show all 1665)
# Title Authors PMID Year
1
Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. 61 54
19861435 2009
2
Mutational status of EGFR and KIT in thymoma and thymic carcinoma. 54 61
18448188 2008
3
Absence of gene mutations in KIT-positive thymic epithelial tumors. 61 54
18486988 2008
4
Expression of p63 in thymomas and normal thymus. 61 54
17276940 2007
5
Carcinoma showing thymus-like differentiation of the thyroid (CASTLE): a comparative study: evidence of thymic differentiation and solid cell nest origin. 61 54
16861971 2006
6
Immunohistochemical KIT (CD117) expression in thymic epithelial tumors. 54 61
16002927 2005
7
Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. 61 54
15201427 2004
8
Tyrosine kinase receptor expression in thymomas. 54 61
14762710 2004
9
Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma. 54 61
14652817 2003
10
Neuroendocrine differentiation is a common feature of thymic carcinoma. 54 61
9737237 1998
11
A case of sarcomatoid carcinoma of the thymus. 54 61
9103218 1997
12
Differential diagnosis of thymic carcinoma and lung carcinoma with the use of antibodies to cytokeratins. 54 61
8523878 1995
13
Carcinoma of the thymus with clear-cell features. Report of eight cases and review of the literature. 54 61
7793482 1995
14
CD5 expression in thymic carcinoma. 61 54
7519823 1994
15
Cytokeratins in normal thymus and thymic epithelial tumors. 54 61
7677978 1993
16
Programmed death-ligand 1 expression profiling in thymic epithelial cell tumors: Clinicopathological features and quantitative digital image analyses. 61
32402921 2020
17
High Neutrophil Count as a Negative Prognostic Factor for Relapse in Patients with Thymic Epithelial Tumor. 61
31993857 2020
18
Feasibility of using dynamic contrast-enhanced MRI for differentiating thymic carcinoma from thymic lymphoma based on semi-quantitative and quantitative models. 61
32197918 2020
19
Interobserver variation in the classification of thymic lesions including biopsies and resection specimens in an international digital microscopy panel. 61
32506527 2020
20
Thymic epithelial tumors: From biology to treatment. 61
32272379 2020
21
Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrence after resection in patients with thymic carcinoma? 61
32535710 2020
22
Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. 61
32179179 2020
23
Superior vena cava replacement combined with venovenous shunt for thymic carcinoma. 61
32534411 2020
24
CD20+ tumor-infiltrating immune cells and CD204+ M2 macrophages are associated with prognosis in thymic carcinoma. 61
32277550 2020
25
Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. 61
32502444 2020
26
PD-L1 expression level in different thymoma stages and thymic carcinoma: a meta-analysis. 61
32366210 2020
27
External compression of the right ventricular outflow tract caused by a malignant thymoma. 61
31769801 2020
28
Fine needle aspiration of thymic epithelial neoplasms and non-neoplastic lesions. 61
32444245 2020
29
Expression of cathepsins B, D and K in thymic epithelial tumours. 61
32467319 2020
30
Evaluating the effectiveness of chemotherapy for thymic epithelial tumors using the CD-DST method. 61
32196982 2020
31
Accuracy of pathologic diagnosis for thymic epithelial tumors: a brief report from an Italian reference Center. 61
32516667 2020
32
The role of needle core biopsies in the evaluation of thymic epithelial neoplasms. 61
32467048 2020
33
En-bloc thymectomy with aortic arch reconstruction under circulatory arrest for invasive malignant thymoma. 61
32353149 2020
34
Exclusive meningeal relapse of a malignant thymoma after a complete response with neoadjuvant chemotherapy. 61
29468565 2020
35
Trans-sternotomy versus video-assisted thoracic surgery for early-stage thymoma patients: a meta-analysis. 61
32420258 2020
36
[Case report of an osseous (and lymphogenic) thymic carcinoma in an adult]. 61
32350550 2020
37
An anti-RNA polymerase III antibody-positive systemic sclerosis patient with thymic carcinoma whose digital ulcers healed during treatment with macitentan and sildenafil for pulmonary arterial hypertension. 61
32281933 2020
38
Thymic lymphoid hyperplasia with Graves' disease in a 28-year-old female: a case report. 61
32420270 2020
39
Paraneoplastic Dermatomyositis as a Potential Precursor to Thymic Carcinoma. 61
31479641 2020
40
Thymic cancer in lynch syndrome: an unusual association. 61
32273268 2020
41
The Role of Adjuvant Therapy in Advanced Thymic Carcinoma: A National Cancer Database Analysis. 61
31877285 2020
42
Proton-Beam Therapy: At the Heart of Cardiac Dose-Sparing in Mediastinal Radiotherapy for Thymic Carcinoma. 61
32353600 2020
43
Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. 61
31771990 2020
44
National incidence and initial therapy for thymic carcinoma in Japan: based on analysis of hospital-based cancer registry data, 2009-2015. 61
32134448 2020
45
Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. 61
31832829 2020
46
[Synchronous Thymic Carcinoma and Primary Lung Cancer]. 61
32393703 2020
47
Double hit: Evans syndrome after malignant thymoma treatment and parvovirus B19 infection. 61
32193179 2020
48
[A Case of Thymic Carcinoma of Postoperative Liver and Mediastinal Lymph Node Metastases Where Long-Term Survival Was Achieved through Multidisciplinary Treatment]. 61
32381931 2020
49
Treatment Outcome and Prognostic Factors of Malignant Thymoma - A Single Institution Experience. 61
32212790 2020
50
Thymic epithelial tumor treatment in Japan: analysis of hospital cancer registry and insurance claims data, 2012-2014. 61
31829410 2020
Sources

Variations for Thymic Carcinoma

About this section

Cosmic variations for Thymic Carcinoma:

9 (show all 36)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87975416 TP53 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
2 COSM91380576 SMAD4 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 6
3 COSM88596522 PREX2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.107G>T p.R36L 8:67952501-67952501 6
4 COSM88408638 NOTCH2 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3359G>A p.C1120Y 1:119937445-119937445 6
5 COSM87667907 KMT2D thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12634C>T p.R4212W 12:49032071-49032071 6
6 COSM88314740 KIT thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1657T>A p.Y553N 4:54727425-54727425 6
7 COSM102181889 KDM6A thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2921C>T p.A974V 23:45078488-45078488 6
8 COSM85170206 IL7R thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 6
9 COSM110448949 FAT1 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12706A>G p.K4236E 4:186596834-186596834 6
10 COSM105695698 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
11 COSM142891951 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
12 COSM142627127 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
13 COSM132270273 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2768C>T p.A923V 23:45078488-45078488 6
14 COSM121944830 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 6
15 COSM106116533 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
16 COSM101719617 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2870C>T p.A957V 23:45078488-45078488 6
17 COSM145420036 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.*1915C>T p.? 23:45078488-45078488 6
18 COSM143359668 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.3005C>T p.A1002V 23:45078488-45078488 6
19 COSM144072853 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.343T>A p.Y115N 17:7675236-7675236 6
20 COSM144363948 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
21 COSM103083119 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.1081C>T p.R361C 18:51065548-51065548 6
22 COSM143857324 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.12712A>G p.K4238E 4:186596834-186596834 6
23 COSM122332176 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 6
24 COSM93250189 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
25 COSM121730466 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.537+1G>T p.? 5:35871214-35871214 6
26 COSM145076506 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
27 COSM122804157 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-21T>A p.? 17:7675236-7675236 6
28 COSM144718880 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
29 COSM139771670 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.793C>T p.R265C 18:51065548-51065548 6
30 COSM144140974 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 6
31 COSM112319052 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
32 COSM143214478 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 6
33 COSM132025397 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.2714C>T p.A905V 23:45078488-45078488 6
34 COSM143433019 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.259T>A p.Y87N 17:7675236-7675236 6
35 COSM111826108 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.376T>A p.Y126N 17:7675236-7675236 6
36 COSM144005441 thymus,NS,thymic carcinoma,undifferentiated carcinoma c.-102T>A p.? 17:7675236-7675236 6
Sources

Expression for Thymic Carcinoma

About this section
Search GEO for disease gene expression data for Thymic Carcinoma.
Sources

Pathways for Thymic Carcinoma

About this section

Pathways related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Cytoskeletal Signaling 4
12.04 MUC1 KRT7 KRT20 KRT19 KRT18
2
Hematopoietic Stem Cells and Lineage-specific Markers 64
11.32 PTPRC KIT CEACAM5 CD5
3
Central carbon metabolism in cancer 36
10.77 TP53 SLC7A5 KIT EGFR
Sources

GO Terms for Thymic Carcinoma

About this section

Cellular components related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell periphery GO:0071944 9.33 PTPRC KRT19 KRT18
2 extracellular exosome GO:0070062 9.28 SLC7A5 PTPRC MUC1 KRT7 KRT19 KRT18
3 intermediate filament GO:0005882 9.26 KRT7 KRT20 KRT19 KRT18

Biological processes related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.63 TP53 PTPRC KRT7 KRT19 KRT18 EGFR
2 keratinization GO:0031424 9.62 KRT7 KRT20 KRT19 KRT18
3 hematopoietic progenitor cell differentiation GO:0002244 9.58 TP53 PTPRC KIT
4 tongue development GO:0043586 9.48 KIT EGFR
5 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.46 TP53 EGFR
6 cerebral cortex cell migration GO:0021795 9.43 NKX2-1 EGFR
7 bone marrow development GO:0048539 9.37 TP53 PTPRC
8 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.26 TP53 MUC1
9 cornification GO:0070268 9.26 KRT7 KRT20 KRT19 KRT18
10 thyroid gland development GO:0030878 8.8 TG PAX8 NKX2-1

Molecular functions related to Thymic Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 TP63 TP53 TG SLC7A5 PTPRC PAX8
2 transcription regulatory region DNA binding GO:0044212 9.56 TP63 TP53 PAX8 NKX2-1
3 MDM2/MDM4 family protein binding GO:0097371 9.16 TP63 TP53
4 p53 binding GO:0002039 9.13 TP63 TP53 MUC1
Sources

Sources for Thymic Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....